Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Recent evidence of sustained benefit with exenatide in Type 2 diabetes

Doggrell, SA (2006). Recent evidence of sustained benefit with exenatide in Type 2 diabetes. Expert Opinion on Pharmacotherapy,7(14):2003-2006.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 6 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title Recent evidence of sustained benefit with exenatide in Type 2 diabetes
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2006
Volume Number 7
Issue Number 14
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33749371050
Start Page 2003
End Page 2006
Total Pages 4
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Exenatide has been shown to improve glycaemic control (over 30 weeks) in subjects with Type 2 diabetes. A recent extension study has shown that, in met formin-treated subjects with Type 2 diabetes, exenatide remained beneficial at 8.2 weeks. For those subjects who completed the study, in addition to the 1% fall in glycosylated haemoglobin (HbA(1c)) at 30 weeks, there was another 0.2% fall in HbA(1c) by 82 weeks. The weight loss achieved was a mean of 3 kg after 30 weeks, and this increased to 5.3 kg after 82 weeks in the completer cohort. In another extension study, continued benefit with exenatide was shown in subjects treated with metformin and/or sulfonylureas. For those subjects who completed the study, in addition to the 0.9% fall in HbA(1c) at 30 weeks, there was another 0.2% fall in HbA(1c) by 82 weeks. The weight loss achieved was a mean of 1.6 kg after 30 weeks, and this increased to 2.1 kg after 82 weeks in the completer cohort. The subjects taking exenatide with metformin had a greater weight loss (5.3 kg), compared with those treated with a sulfonylurea (3.9 kg) and those taking metformin and a sulfonylurea (4.1 kg). in conclusion, extension studies have confirmed that exenatide is an exciting new and useful medicine for Type 2 diabetes.
Keywords exenatide
metformin
sulfonylureas
type 2 diabetes mellitus
metformin-treated patients
glycemic control
exendin-4
weight
sulfonylurea
therapy
DOI http://dx.doi.org/10.1517/14656566.7.14.2003   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 31 Abstract Views  -  Detailed Statistics
Created: Wed, 28 Nov 2007, 14:16:08 CST